📺 Stream EntrepreneurTV for Free 📺

A New Weight-Loss Drug Could Be a Complete Game Changer. 'Psychologically, You Don't Want to Eat.' Mounjaro, a diabetes drug used to treat obesity, is forecast to make $50 billion in sales annually.

By Jonathan Small

entrepreneur daily

Opinions expressed by Entrepreneur contributors are their own.

In recent months, there has been a swelling interest in using diabetes drugs to treat weight loss.

Drugs with brand names such as Ozempic and Wegovy have become so popular with Hollywood celebrities and TikTokers; it's led to a nationwide shortage for diabetics.

But the anti-obesity drug craze is about to be rocked by another major development. The diabetes drug Mounjaro could be approved by the U.S. Food and Drug Administration (FDA) for weight loss later this year, according to manufacturer Eli Lilly. The company just completed a late-stage study of the drug for weight loss and found the participants lost more than 50 pounds in nearly 17 months.

"We have not seen this degree of weight reduction," Dr. Nadia Ahmad, Lilly's medical director of obesity clinical development, told CBS News.

Analysts predict that Mounjaro, tirzepatide generically, could become one of the biggest-selling drugs ever. Evaluate Pharma estimates as much as $50 billion in sales by 2028. To put this in perspective, Novo Nordisk, which makes Ozempic and Wegovy, reported combined sales of about $2.4 billion in 2022.

How does Mounjaro work?

Mounjaro was approved by the FDA last year to treat Type 2 diabetes. Patients take it via injection once per week. The drug works by activating two hormones naturally produced in the body that help to reduce appetite and increase feelings of fullness. It also curbs craving signals chemically sent from the gut to the brain.

"Psychologically, you don't want to eat," said Matthew Barlow, a health technology executive, told CBS News. "Now I can eat two bites of a dessert and be satisfied."

Though trials have shown the drugs to be safe, side effects include nausea and constipation.

Mounjaro isn't cheap. A monthly dose can run as much as $1,400. But if the FDA approves it for weight loss, people prescribed the medication for obesity could more easily be covered by insurance.

Jonathan Small

Entrepreneur Leadership Network® VIP

Founder, Write About Now Media

Jonathan Small is an award-winning author, journalist, producer, and podcast host. For 25 years, he has worked as a sought-after storyteller for top media companies such as The New York Times, Hearst, Entrepreneur, and Condé Nast. He has held executive roles at Glamour, Fitness, and Entrepreneur and regularly contributes to The New York Times, TV Guide, Cosmo, Details, Maxim, and Good Housekeeping. He is the former “Jake” advice columnist for Glamour magazine and the “Guy Guru” at Cosmo.

Want to be an Entrepreneur Leadership Network contributor? Apply now to join.

Side Hustle

These Coworkers-Turned-Friends Started a Side Hustle on Amazon — Now It's a 'Full Hustle' Earning Over $20 Million a Year: 'Jump in With Both Feet'

Achal Patel and Russell Gong met at a large consulting firm and "bonded over a shared vision to create a mission-led company."

Business News

These Are the 10 Most Profitable Cities for Airbnb Hosts, According to a New Report

Here's where Airbnb property owners and hosts are making the most money.

Business News

Samsung's New Ad Pokes Fun at Apple's Controversial 'Crush' Ad

Creative universes overlap in a new ad from Samsung.

Starting a Business

This Couple Turned Their Startup Into a $150 Million Food Delivery Company. Here's What They Did Early On to Make It Happen.

Selling only online to your customers has many perks. But the founders of Little Spoon want you to know four things if you want to see accelerated growth.

Productivity

Want to Be More Productive? Here's How Google Executives Structure Their Schedules

These five tactics from inside Google will help you focus and protect your time.